The stock may face downward pressure due to declining core sales and profitability. Traders should monitor whether the new formulary approvals and marketing initiatives for Renacidin® translate into measurable revenue recovery in the next few quarters.
Price Chart
Executive Summary
United-Guardian reported a 13% decline in net sales and a 35% drop in net income for FY 2025 compared to FY 2024, driven by reduced demand for cosmetic ingredients, particularly in China, and inventory overstock at its key distributor. While pharmaceutical and medical lubricant sales grew 15% and 4% respectively, the overall financial performance was materially weaker year-over-year.
Key Financial Metrics
Key Facts
- Net sales declined 13% from $12.18M in 2024 to $10.55M in 2025
- Net income dropped 35% from $3.25M to $2.11M, with EPS falling from $0.71 to $0.46
- Cosmetic ingredient sales weakened due to excess inventory at Ashland Specialty Ingredients and reduced demand in China
- Pharmaceutical sales increased 15% and medical lubricants up 4%, driven by stronger demand and lower Medicare rebates
- Company secured formulary approvals for Renacidin®, which may support future growth
Financial Impact
Revenue down $1.64M YoY, net income down $1.14M, EPS down $0.25
Risk Factors
- Continued weakness in cosmetic ingredient demand, especially in China
- Reliance on distributor inventory normalization for sales recovery
- Forward-looking optimism not supported by current financial trends
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263783 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 7, 2026 11w ago | Press Release | $7.29 | awaiting T+60 | — | $6.65 (−8.78%) |
Jul 16, 2026 14w ago | 8-K | $7.50 $7.00 | ▼ −6.67% | ▼ −10.38% | $6.65 (−11.33%) |
May 8, 2026 24w ago | 8-K | $6.87 $7.10 | ▲ +3.35% | ▼ −1.49% | $6.65 (−3.20%) |
May 8, 2026 24w ago | Press Release | $6.87 $7.10 | ▲ +3.35% | ▼ −1.49% | $6.65 (−3.20%) |
Mar 27, 2026 30w ago | Press Release | $6.56 $7.11 | ▼ −8.38% | ▲ +7.68% | $6.65 (−1.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers